Biotech Co.*


Pharma Co.

Type/Product Area

Terms/Details (Date)


Boehringer Ingelheim International GmbH (Germany)

BI got worldwide rights to AbGenomics' antibody 168, which is targeted to a range of immune-related diseases

AbGenomics kept an option to co- promote resulting products in certain Asian countries; terms of the deal were not disclosed (6/6)

Health Ltd.*


Mead Johnson
Nutritionals (unit
of Bristol-Myers Squibb Co.)

Research and cross-licensing deal covering nutritional applications of novel ingredient technologies for infants and children

Each will contribute intellectual property to the research, and they will jointly fund development programs (4/28)@



Co. Ltd. (China)

They finalized a deal covering the development and sales of Alliance's Oxygent in China

Alliance will get up-front fees and is eligible
for milestone and royalty payments (5/16)



Novartis Pharma AG (Switzerland)

Exclusive deal to develop ANA975 and additional Toll-like receptor 7 oral prodrugs for hepatitis B and C and possibly other infectious diseases

Anadys gets an initial license payment of $20M and up to $550 million in regulatory and commercial milestone payments; Anadys also has an option to retain 35% of profits in the U.S. by contributing 35% of costs; otherwise it would get royalties on any resulting sales (6/2)



Daiichi Suntory Pharma Co. Ltd. (Japan)

BioMarin licensed tetrahydro-biopterin (6R-BH4) to treat the endothelial dysfunction that causes vascular complications in various diseases

BioMarin previously licensed rights to the drug for use in genetic diseases, including phenylketonuria; Daiichi gets an up-front payment, development milestones for up to two indications, and royalties on any sales (5/5)

BioXell SpA*

Merck & Co. Inc.

Merck got exclusive rights to develop TREM-related therapeutic and diagnostic products; TREM is Triggering Receptors Expressed on Myeloid Cells

BioXell gets an up-front payment and up to $150M in milestone payments, including $55.5M for successful development of the first product for the first indication; it also would get royalties on any sales (5/23)



Olympus Corp. (Japan)

Deal to develop a hybrid DNA- based and protein-based diagnostic test for lung cancer

Cangen gets access to Olympus' microarray technology in the deal, terms of which were not disclosed (5/25)

Cellzome Inc.*

Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson)

Ortho exercised its option to develop Cellzome's Gamma Secretase Modulator program

The license stems from a March 2005 deal in Alzheimer's disease; Cellzome gets an additional technology access fee and continued research funding, as well as potential milestone and royalty payments (5/23)

Cerus Corp.
(CERS) and
International Inc.

BioOne Corp. (Japan)

Definitive agreement calls for BioOne to commercialize the Intercept Blood System for plasma in much of Asia

Cerus already received $3M when a letter of intent was signed in January; potential up-front and milestone payments total $33M in cash and BioOne equity; Cerus also would get royalties on sales in the covered countries (6/6)


Systems Inc.

(Canada; TSE:CHR)

Pfizer Inc.

Pfizer got rights to use the ACE System to develop cell lines for research, development and manufacturing purposes

The deal represents an expansion of a December 2004 deal under which Chromos is using the system to engineer cell lines to express a Pfizer protein; terms were not disclosed (5/30)

Codexis Inc.*

Bristol-Myers Squibb Co.

Deal to improve biocatalyst productivity for an undisclosed product candidate from BMS

Codexis gets research funding and a potential milestone payment; BMS may opt at that point to fund further research, which involves Codexis' re-engineering platform (5/24)


Fournier Pharma (France)

Collaboration under which ComGenex will provide exclusive chemistry services to Fournier for three years

Fournier extended an initial 16-month project into the multiyear collaboration, terms of which were not disclosed (5/17)


Ortho-Clinical Diagnostics Inc. (unit of Johnson & Johnson)

Deal to develop diagnostic products based on biomarkers discovered by Compugen; Ortho initially can develop up to nine biomarkers

Ortho gets worldwide rights to resulting products; Compugen is entitled to license fees and milestone payments for each biomarker, as well as royalties on any sales (6/8)

BioPharma Inc.*

Lupin Ltd. (India)

Collaboration to develop a drug delivery system for an anti-infective product

Lupin gets up to $10.5M in milestone and other payments, and royalties on any sales; Cornerstone has marketing rights in the U.S. (5/9)

Crucell NV
(the Netherlands;

Ferring Pharmaceuticals A/S (Denmark)

Ferring got rights to use the PER.C6 cell line in the field of women's health care

The deal includes Crucell's allied contract manufacturer DSM Biologics; terms were not disclosed (5/25)


Sigma-Aldrich Corp.

Sigma-Aldrich got exclusive, worldwide rights to commercialize Cyntellect's Cell Xpress service

Cyntellect got a multimillion-dollar equity investment, and will get royalties on sales; Sigma-Aldrich also will pay for internal use of Cyntellect's LEAP technology (4/27)@

Cytogen Corp.

The Dow Chemical Co.

Cytogen and Dowpharma are collaborating to create a targeted product for treating prostate and other cancers

Dow technology will be used to radiolabel Cytogen's PSMA antibody (7E11); the deal extends an existing agreement; terms were not disclosed (5/10)

Diatos SA*

Servier (France)

Deal to apply Diatos' Vectocell technology to a small-molecule cancer candidate from Servier

Servier will fund work at Diatos, and gets an option to license resulting technology (5/17)



Bayer HealthCare LLC

Bayer Diagnostics got exclusive rights to Eragen's MultiCode-PLx System for use in cystic fibrosis

Bayer also got rights to a create assays for other disease states; MultiCode-PLx is a high-throughput genotyping system; terms of the deal were not disclosed (5/18)



Allergan Inc.

They extended deal from 2003 to develop drugs for neurodegenerative diseases, pain and ophthalmology

ExonHit got a $2M payment and continues to receive R&D support; it also is entitled to milestone and royalty payments, and has certain co-development and co- commercialization options (5/17)

454 Life

by CuraGen
Corp.; CRGN)

F. Hoffmann-La Roche Ltd. (Switzerland)

Exclusive five-year deal for sales and distribution of 454's nanotechnology- based genome-sequencing systems

454 will get up to $62M in license fees, milestones related to instrument releases, minimum royalties and research funding; it also would get royalties on sales (5/12)

Pharma plc


Syngenta Biopharma (Switzerland)

Fulcrum will provide development services for Syngenta

The focus is on advancing Syngenta projects toward clinical development; terms of the deal were not disclosed (5/18)

GeneGo Inc.*

Procter & Gamble Pharmaceuticals Inc.

P&G licensed MetaCore and MetaBase technologies from GeneGo

The products are used in life science research; terms of the deal were not disclosed (5/9)


DaeWoong Pharmaceutical Co. Ltd. (South Korea)

Collaboration to progress the clinical development of antibody therapeutics targeted to bacterial infections

They will combine Haptogen's discovery approach with the formulation, manufacturing and marketing expertise of DaeWoong; terms were not disclosed (5/17)


Novartis Pharma AG (Switzerland)

Collaboration to discover and develop Toll-like receptor 9 drugs targeting asthma and allergy

First they will evaluate immune modulatory oligonucleotide candidates; Hybridon then could earn up-front license fees along with milestone payments that could total $136M, as well as royalties on sales (6/1)



Merck & Co. Inc.

Merck exercised an option for a nonexclusive license to an additional antigen to be used with Inovio's MedPulser DNA Delivery System

Inovio gets an option fee and remains eligible for milestone and royalty payments; Merck now has licensed three antigens under their 2004 license agreement (5/12)


Daiichi Pharmaceutical Co. Ltd. (Japan)

Daiichi licensed Inpharmatica's Admensa Interactive technology

The technology is a suite of predictive ADME models and compound-prioritization tools; terms were not disclosed (6/6)

Intra-Cellular Therapies Inc.*

Bristol-Myers Squibb Co.

ITI got worldwide rights to a family of preclinical compounds targeting central nervous system diseases

BMS receives an undisclosed license fee up front, and potential milestone and royalty payments (6/1)



Pfizer Inc.

Deal to identify second- generation antisense drugs for treating ophthalmic disease

Isis gets a $1M technology access fee and research funding, and is eligible to receive milestone and royalty payments (5/24)

Kiadis BV*
(the Netherlands)

NV Organon (the Netherlands; unit of Akzo Nobel)

Deal to evaluate Kiadis' BioSelect screening technology in Organon's reproductive medicine discovery program

Kiadis intends to deliver novel active compounds against the target provided by Organon; terms of the deal were not disclosed (5/25)

Large Scale
Biology Corp.


(unit of Bayer AG)

Collaboration to investigate the plant-based expression of LSBC's lysosomal acid lipase

The goal is to develop a therapeutic product; terms of the deal were not disclosed (4/29)

Lexicon Genetics Inc. (LEXG)

NV Organon (the Netherlands; unit of Akzo Nobel)

Collaboration under which Lexicon will create and analyze mouse knockouts of 300 genes to identify drug targets

They will share R&D costs and any revenue; Lexicon gets $22.5M up front, and research funding of up to $50M a year during the four-year target-function discovery portion of the alliance (5/17)

Macrocyclics Inc.*

MDS Nordion (Canada)

Deal to develop bifunctional chelates for use in molecular imaging and targeted therapeutics

Terms of the three-year deal were not disclosed (5/26)

Medarex Inc.

Ono Pharmaceutical Co. Ltd. (Japan)

Collaboration to research and develop a fully human anti-PD-1 antibody for treating cancer

They will share costs through Phase II trials; then each would be responsible for its own territory; Medarex has rights in North America, Ono everywhere else (5/12)


Astellas Pharma Inc. (Japan)

They extended for one year a 2002 deal to validate drug targets for the treatment of Type II diabetes and obesity

Metabolex gets research funding and mile- stone payments under the extension; it would receive royalties on any sales, and retained co-promotion rights in North and South America (5/2)


F. Hoffmann-La Roche Ltd. (Switzerland)

Miikana got worldwide rights to Roche's MKC-1, an anticancer agent in Phase II trials

Roche gets an equity stake in Miikana, as well as undisclosed up-front, milestone and royalty payments (5/3)


GlaxoSmithKline plc (UK)

Morphotek will apply its Morphodome technology to GSK's antibody producer lines to develop cell lines with improved characteristics

Morphotek gets R&D funding for an initial project, which could lead to two more projects; Morphotek also could receive annual fees, and is eligible for milestone payments (5/18)

Myogen Inc.

Novartis AG (Switzerland)

They expanded a deal from 2003 to include Myogen's histone deacetylase inhibitor program

The expansion extends research funding for at least three years and includes undisclosed signing fees, as well as milestone and royalty provisions; Myogen also has certain co-promotion and profit-sharing options (5/26)


Medtronic Inc.

Deal to develop and market micro- infusion catheters to deliver gene therapy into the brain and central nervous system

Neurologix got a $2M equity investment in the deal; Medtronic is entitled to milestone payments, and they would share revenues from any resulting device (5/2)

Thera Inc.*

Pfizer Inc.

They expanded a deal to profile compounds across Odyssey's panel of cell-based assays

The project will focus on 500 compounds from multiple therapeutic areas; terms of the deal were not disclosed (5/17)



Par Pharmaceutical Co. Inc.

Collaboration on a narrow- spectrum antibiotic (now named PAR-101) active against Clostridium difficile; it is in Phase II trials

Par acquired a 16% partnership interest in Optimer; Optimer will fund development; Par would pay royalties on sales, and has an option to develop three other Optimer compounds (5/3)

BioMedica plc


Pfizer Inc.

Pfizer got rights to use the LentiVector gene delivery system for research activities

Oxford BioMedica gets an up-front license payment and annual maintenance fees; further terms were not disclosed (6/6)



Astellas Pharma Inc. (Japan)

Collaboration to advance the development of a series of Astellas preclinical compounds

Portola scientists have identified the anti- thrombotic properties of the compounds; terms of the deal were not disclosed (6/6)

Prosidion Ltd.
(UK; unit of OSI
Inc.; OSIP)

Undisclosed company

The unnamed firm got non- exclusive rights to use DPIV inhibitors for Type II diabetes and related conditions

The agreement covering dipeptidyl peptidase IV inhibitors includes undisclosed upfront, milestone and royalty payments to Prosidion (5/12)


Teva Pharmaceuticals Industries Ltd. (Israel)

Deal to study the feasibility of using drugs targeting ubiquitin ligases for cancer therapy

Teva made an equity investment as part of the deal, and has an option to license the program; if so, Proteologics would be enti- tled to milestone and royalty payments (5/3)

Pharmaceuticals Inc.*

Sumitomo Pharmaceuticals Co. Ltd. (Japan)

Deal to develop and commercialize SMP-601, Sumitomo's injectable antibiotic, in North America and Europe

Protez will provide development and commercialization milestones, as well as royalties on any sales; its license is exclusive in NorthAmerica and Europe (5/17)

Renovis Inc.

Pfizer Inc.

Worldwide deal to develop small molecules that target the vanilloid receptor, VR1, for treating pain, urinary incontinence and other conditions

They will combine their current VR1 R&D programs; Renovis gets a $10M license fee and more than $7M in research funding over two years; Renovis also can earn $170M in milestone payments for each resulting product, as well as royalties on sales (5/31)

Genetics Inc.*

Roche Diagnostics (Switzerland) and Eli Lilly and Co.

Deal to confirm biomarkers for use to identify patients most likely to respond to certain cancer therapies

Roche and Lilly entered a collaboration initially focused on Lilly's Alimta and Gemzar; they will work with Response Genetics on biomarker tests (5/11)

Biotech Ltd.

(China; AMEX:SVA)

LG Life Sciences Ltd. (South Korea)

They agreed to collaborate on marketing efforts and vaccine supply for China and international markets

They will work on international marketing of Sinovac's Healive hepatitis A vaccine; Sinovac will introduce LG's HepB vaccines into China; and they jointly will work on Sinovac's influenza vaccine (Anflu); terms of the deal were not disclosed (5/18)

Valentis Inc.

Schering AG (Germany)

Expanded deal gives Schering nonexclusive rights to use GeneSwitch and PINC technologies in its research

Valentis gets up-front license fee and is entitled to yearly maintenance fees; an earlier deal gave Schering rights to the technologies for use with two genes (6/7)

Valentis Inc.

Organon Laboratories Ltd. (UK)

Organon licensed rights to use Valentis' GeneSwitch gene-regulation technology for research purposes

Valentis got a license fee and is entitled to yearly license maintenance fees; further terms of the nonexclusive license were not disclosed (5/25)

Vical Inc.

Merck & Co. Inc.

Merck exercised three options under an existing deal, giving it rights to use Vical's nonviral gene delivery technology in cancer vaccine applications

Vical gets a $3M payment and it entitled to milestone and royalty payments; Vical also has certain co-promotion rights for resulting products (6/8)


Bristol-Myers Squibb Co.

Three-year deal under which BMG got rights to immortalized Fa2N-4 hepatocytes for internal testing purposes

Terms were not disclosed; XenoTech is licensee of the technology from MultiCell Technologies Inc. (5/23)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

@ News occurred before the time frame of this chart but was not included in the previous chart.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.